外周血T淋巴细胞亚群检测在再生障碍性贫血患者中的作用以及临床意义

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (410 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the level of T lymphocyte subsets in peripheral blood of patients with aplastic anemia (AA) and its clinical significance. Methods A total of 70 AA patients treated at Huaibei People’s Hospital from January 2017 to April 2020 were selected as the observation group, of which 30 patients were severe AA (severe AA group) and 40 patients were non-severe AA (non-severe AA group), and 40 healthy people were selected as the control group. After receiving treatment in the observation group, 45 cases were relieved (remission group), (including significant improvement, remission and basic cure), and 25 cases were not remission (non-remission group). The levels of natural killer (NK) cells, regulatory T (Treg) cells, CD4+, CD3+, CD8+, CD4+/CD8+, and Treg+/CD4+ were detected by flow cytometry. Results In the observation group, the celluar levels of NK, Treg, CD4+, CD4+/CD8+, and Treg+/CD4+ were all lower than those in the control group, and CD3+ and CD8+ were higher than those in the control group (P ＜ 0.01). The celluar level of Treg, CD4+, CD4+/CD8+, and Treg+/CD4+ in the severe AA group were lower than those in the non-severe AA group (P ＜ 0.05). The Treg cells and CD4+/CD8+ in the non-remission group were lower than those in the remission group (P ＜ 0.05). In patients with AA, the areas under the curve of Treg cells and CD4+/CD8+ predicting AA disease remission were 0.71 and 0.75, the area under the curve for the combination of the two was 0.82, the specificity was 67.5%, and the sensitivity was 85.1%. Conclusion Patients with AA have abnormal distribution of T cell subsets. Treg combined with CD4+/CD8+ have certain value in assessing the condition and treatment effect.

Key words： Aplastic anemia Immune function Lymphocytes Regulatory T cells CD4+ T cells CD8+ T cells

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Huijie LI Chenpeng GAI Can

Cite this article:

HAN Huijie LI Chenpeng GAI Can. The role and clinical significance of peripheral blood T lymphocyte subsets in patients with aplastic anemia[J]. 中国医药导报, 2021, 18(11): 78-81.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I11/78

[1] 王佳，吴湘如，覃霞，等.儿童获得性再生障碍性贫血和难治性血细胞减少的骨髓组织病理学观察[J].中华病理学杂志，2020，49（7）：699-703.
[2] 杨洁茹，王化泉，邵宗鸿.再生障碍性贫血发病机制的研究进展[J].中华血液学杂志，2019，40（9）：796-800.
[3] 孙莹莹，刘春燕，邵宗鸿.获得性再生障碍性贫血发病机制及遗传学异常研究进展[J].中华内科杂志，2019，58（5）：401-404.
[4] Guan J，Sun Y，Fu R，et al. A cohort study of immune and hematopoietic functionality changes in severe aplastic anemia patients treated with immunosuppressive therapy [J]. Medicine（Baltimore），2019，98（3）：e14149.
[5] 郁志，黄桂璇，张玉平，等.再生障碍性贫血患者CD4+T细胞中共刺激分子和免疫抑制受体的表达特点和意义[J].中国病理生理杂志，2020，36（7）：1314-1319.
[6] Hosokawa K，Muranski P，Feng X，et al. Memory Stem T Cells in Autoimmune Disease： High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia [J]. J Immunol，2016，196（4）：1568-1578.
[7] Dao AT，Yamazaki H，Takamatsu H，et al. Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia[J]. Ann Hematol，2016，95（5）：771-781.
[8] Qi W，Ren Y，Fu R，et al. Detection and Significance of CD4+CD25+CD127dim Regulatory T Cells in Individuals with Severe Aplastic Anemia[J]. Turk J Haematol，2015， 32（3）：220-227.
[9] 刘景珍，葛一蓉，饶媚.再生障碍性贫血患者血浆IL-35表达水平及其与Tregs细胞的关系研究[J].实用医院临床杂志，2018，15（5）：73-76.
[10] 张之南，沈悌.血液病诊断及疗效标准[M].第3版.北京：科学出版社，2007：19-23.
[11] 邵宗鸿，张连生.再生障碍性贫血诊断与治疗中国专家共识（2017年版）[J].中华血液病学杂志，2017，38（1）：1-5.
[12] 季艳萍，孙自敏.重型再生障碍性贫血治疗进展[J].器官移植，2020，11（2）：293-297，310.
[13] 刘春燕.免疫异常——导致再生障碍性贫血发病的重要因素[J].中华医学杂志，2019，99（26）：2011-2013.
[14] 孙莹莹，刘春燕，邵宗鸿.获得性再生障碍性贫血发病机制及遗传学异常研究进展[J].中华内科杂志，2019， 58（5）：401-404.
[15] 王一.再生障碍性贫血患者外周血淋巴细胞亚群分布异常的临床研究[J].中国卫生检验杂志，2019，29（16）：1971-1973.
[16] 俞颖，朱琳超，李强，等.铁过载对再生障碍性贫血患者外周血淋巴细胞亚群的影响[J].浙江医学，2020，42（8）：766-769.
[17] 钟敏，苏群豪，胡敏，等.新发重型再生障碍性贫血患者外周血CD4+CD25+T细胞及其细胞因子表达观察[J].山东医药，2019，59（9）：74-76.
[18] 丁少雪，付蓉.重型再生障碍性贫血患者免疫抑制治疗疗效预测及恢复规律研究进展[J].中华血液学杂志，2018， 39（11）：960-964.
[19] Savasan S. Acquired Aplastic Anemia： What Have We Learned and What Is in the Horizon?[J]. Pediatr Clin North Am，2018，65（3）：597-606.
[20] Nakao S，Feng X，Sugimori C. Immune pathophysiology of aplastic anemia [J]. Int J Hematol，2005，82（3）：196-200.
[21] Zheng M，Liu C，Fu R，et al. Abnormal immunomodulatory ability on memory T cells in humans with severe aplastic anemia[J]. Int J Clin Exp Pathol，2015，8（4）：3659-3669.
[22] Risitano AM. （Auto-）immune signature in aplastic anemia [J]. Haematologica，2018，103（5）：747-749.
[23] Lu T，Liu Y，Li P，et al. Decreased circulating Th22 and Th17 cells in patients with aplastic anemia [J]. Clin Chim Acta，2015，450：90-96.
[24] Yamazaki H. Acquired aplastic anemia：recent advances in pathophysiology and treatment [J]. Rinsho Ketsueki，2018，59（6）：711-715.
[25] 陈苗，吴亚妹，周道斌，等.强化免疫抑制治疗和单倍体移植治疗年轻重型再生障碍性贫血的比较[J].基础医学与临床，2020，40（6）：759-764.
[26] 罗东凤.造血生长因子对成人再生障碍性贫血伴严重感染患者的疗效分析[J].中国现代医生，2020，58（28）：59-62.
[27] 陈小洁，苑召虎，阳雪新，等.CD4+CD25+调节性T细胞及转化生长因子-1在血小板输注无效患者中的表达和意义[J].中国医药导报，2019，16（16）：80-83.
[28] 肖捷，杨丽萍，肖健，黄继贤.CD4+CD25+调节性T细胞在AIHA患者外周血中的表达及临床意义[J].中国医药科学，2020，10（16）：199-202.